Goodwin Procter announced today the release of the 2016 edition of Biosimilars: A Guide to Regulatory and Intellectual Property Issues. The guide provides clarity to the complex, developing regulatory and legal framework around biosimilars, and the 2016 update offers analysis on the first waves of patent litigation related to biosimilars – including the pivotal Amgen v. Sandoz case – and important market developments around the globe.
For more information and to request your copy of the guide, please click here.